Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

11 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

NCT01302834 Quality of Life - RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S) - 3183758v1.0 - RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S)

- 09/01/2015 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Header Module, HEARING HANDICAP INVENTORY FOR ADULTS SCREENING QUESTIONNAIRE (NEWMAENT AL., 1990; NEWMAENT AL., 1991)
RTOG 1016 QN: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Hearing Handicap Inventory for Adults (HHIA-S) Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9A132BA5-9085-FFE2-E040-BB89AD43727A

dbGaP phs001202 OncoArray: Oral and Pharynx Cancer - pht005773.v1.p1

- 22/05/2023 - 5 Formulaires, 1 Groupe Item, 5 Eléments de données, 1 Langue
Groupe Item: pht005773
Principal Investigator: Paul Brennan, PhD, International Agency for Research on Cancer (IARC), Lyon, France MeSH: Head and Neck Neoplasms,Mouth Neoplasms,Pharyngeal Neoplasms,Oropharyngeal Neoplasms,Hypopharyngeal Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001202 Genetic factors play an important role in susceptibility to head and neck cancer and could also explain differences in response to treatment and outcome. The goal of this project is to investigate genetic variation involved in oral and oropharyngeal cancer susceptibility by performing the largest GWAS on these diseases, using a novel genotyping tool specifically designed for cancer studies by the OncoArray Network. This project encompasses data from approximately 6000 oral and pharynx cancer cases and 4000 controls derived from 12 epidemiological studies most of case-control design. The genotyping was centralized at the Center for Inherited Disease Research (CIDR), and the epidemiological data harmonization and analysis were completed at the International Agency for Research on Cancer (IARC). This study was supported by National Institute of Dental and Craniofacial Research (NIDCR) with direct funding to CIDR.

pht005774.v1.p1

1 Groupe Item 5 Eléments de données

pht005775.v1.p1

1 Groupe Item 8 Eléments de données

Eligibility

1 Groupe Item 1 Élément de données

pht005776.v1.p1

1 Groupe Item 6 Eléments de données

Initial Evaluation Oropharyngeal Cancer RTOG 1016 I1NCT01302834

- 04/08/2015 - 1 Formulaire, 11 Groupes Item, 85 Eléments de données, 1 Langue
Groupes Item: Header Module, Patient demographics, Tumor Measurements At Presentation, Basis of Diagnosis, Laboratory Values, Primary Site, Staging, PRIOR TREATMENT, SEVERE ACTIVE COMORBIDITIES, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., Footer Module
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=94417A43-2D71-18EF-E040-BB89AD432749

Eligibility Dysphagia NCT01748942

- 29/11/2019 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01748942

Eligibility Carcinoma NCT00728130

- 10/11/2017 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Anatomical Relationship of Level IB Lymph Nodes to the Submandibular Gland in Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00728130

Eligibility HPV Positive Oropharyngeal Squamous Cell Carcinoma NCT01855451

- 02/03/2020 - 1 Formulaire, 2 Groupes Item, 34 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01855451

Eligibility Early-Stage Squamous Cell Carcinoma of the Oropharynx NCT01590355

- 03/12/2019 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR); ODM derived from: https://clinicaltrials.gov/show/NCT01590355

NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form

- 08/07/2015 - 1 Formulaire, 12 Groupes Item, 67 Eléments de données, 1 Langue
Groupes Item: RTOG clinical trial administrative data, Summary of Systemic Treatment, ARM 1 ONLY - DAY 1, DAY 22, Header, ARM 2 ONLY - WEEK 1 - INITIAL DOSE, WEEK 2-8, Non-Protocol Therapy, Tube feeding, Protocol Specific Adverse Event Evaluation: Use the CTC AE version 4 (MedDRA 12) to code all events., New or continuing adverse events, Comments
NCT01302834 RTOG 1016 TF: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Treatment Summary Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9418B248-C31D-807C-E040-BB89AD431782

NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form

- 08/07/2015 - 1 Formulaire, 9 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: Header Module, Vital status, Tumor Measurements At Presentation, RECURRENCE OR PROGRESSION, New primary cancer, NON-PROTOCOL THERAPY, Protocol Specific Adverse Event Evaluation, New or continuing adverse events, Comments
NCT01302834 RTOG 1016 F0: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9550D538-F61F-EAB4-E040-BB89AD4377BB

NCT01302834 RTOG 1016 F1: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form

- 08/07/2015 - 1 Formulaire, 8 Groupes Item, 44 Eléments de données, 1 Langue
Groupes Item: RTOG clinical trial administrative data, Patient status assessment, RECURRENCE OR PROGRESSION, New primary cancer, Non-protocol Therapy, Protocol Specific Adverse Event Evaluation, New or continuing adverse events, Comments
NCT01302834 RTOG 1016 F1: Radiation Therapy Oncology Group Phase III Head and Neck Cancer Follow-Up Form Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=944181D6-4EF9-82FB-E040-BB89AD43799B

NCT01302834 Quality of Life - RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment - 3159842v1.0 - RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment

- 09/01/2015 - 1 Formulaire, 6 Groupes Item, 51 Eléments de données, 1 Langue
Groupes Item: Header Module, PRO-CTCAE Assessment, PRO-CTCAE Assessment (cont.1), PRO-CTCAE Assessment (cont.2), PRO-CTCAE Assessment (cont.3) , PRO-CTCAE Assessment (cont.4)
RTOG 1016 PQ: Radiation Therapy Oncology Group Phase III Head and Neck Cancer PRO-CTCAE Assessment Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=95331A4F-A6A2-25A3-E040-BB89AD432C5C

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial